Logo-Cardalis-usa

Efficacy and Safety

cardalis-us-2

A faster improvement in clinical signs has been observed compared to benazepril alone 1,2,3

clinical-sign-graph

Improvement of heart failure symptoms: difference between the time to improvement observed in dogs treated with benazepril alone versus dogs treated with CARDALIS™ (significant difference p<0.05).

…and safe when used with concomitant therapy(e.g., furosemide)4

kidneys

Renal parameters mean values:

• remained within the reference range
• did not change significantly over the 12-month study duration

The BESST Study - a pivotal efficacy study for FDA approval of CARDALIS™5

dog-icon 569 dogs enrolled in the study
 

fewer-treatment-failures

cardalis-better-benezapril-graph

 

 

* Treatment failure = occurrence of cardiac death/euthanasia due to cardiac cause or worsening/occurrence of cardiac signs

LARGEST CLINICAL TRIAL CONDUCTED TO DATE IN CARDIAC DOGS

survival-times-graph

cardalis-dog

CARDALIS resulted in a statistically significant improvement in survival times for CHF patients* in a recently completed clinical trial5.

 

 

 

 

Cardalis Palatability

for patient compliance

FIND OUT MORE
chewable-for-dogs

References 

  1. Data on file: Cardalis™. Marketing authorization file, CEVA Santé Animale, 2012.
  2. Cardalis™. CVMP assessment report. EMA. August 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/veterinary/002524/WC500131472.pdf
  3. Cardalis™. EPAR product information. June 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002524/WC500131473.pdf.
  4. Freedom of Information Summary, NADA #141-538 (July 27, 2020), CARDALIS.
  5. Coffman, M Guillot, E Blondel, T, et al. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)J Vet Intern Med 2021 1 15
    https://doi.org/10.1111/jvim.16155

CARDALIS and the CARDALIS logo trademarks are the property of Ceva Santé Animale S.A.

Important Safety Information

Do not administer in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) in dogs with renal insufficiency. Do not use in dogs with hypoadrenocorticism (Addison’s disease), hyperkalemia or hyponatremia.  Do not use in dogs with known hypersensitivity to ACE inhibitors or spironolactone. The safety and effectiveness of concurrent therapy of CARDALIS™ with pimobendane has not been evaluated. The safety of CARDALIS™ has not been evaluated in pregnant, lactating, breeding, or growing dogs. CARDALIS™ administration should begin after pulmonary edema is stabilized. Regular monitoring of renal function and serum potassium levels is recommended. Common side effects from a field study include anorexia, vomiting, lethargy, diarrhea and renal insufficiency.